Dermatol. praxi. 2021;15(4):186-190 | DOI: 10.36290/der.2021.035

Treatment of acne from a gynecologist's point of view

doc. MUDr. Peter Koliba, CSc.1, MUDr. Markéta Dibonová1, 2, MUDr. Karolína Bortelová3
1 Gynartis, s. r. o. - gynekologická ambulance, Ostrava-Poruba
2 Gynekologicko-porodnické odd. Nemocnice ve Frýdku-Místku
3 Dětské kožní oddělení Pediatrické kliniky, Dětská nemocnice FN Brno

Acne is one of the most common chronical skin diseases and is one of the common skin manifestations accompanying puberty. The authors try to summarize the basic information about this skin disease in a review, interdisciplinary article and focus on the diagnosis and treatment of acne in women from the point of view of a gynecologist. Skin manifestations are often associated with elevated levels of androgens - hyperandrogenism. Especially in these cases, an interdisciplinary approach is suitable, which requires comprehensive diagnosis and therapy, in order to treat this condition comprehensively and causally. Although acne treatment is and will be the domain of dermatologists, the interdisciplinary approach of dermatologists, endocrinologists and gynecologists should be a matter of course nowadays.

Keywords: acne, acne vulgaris, hyperandrogenic syndrome, combined oral contraception (COC), hormonal treatment, puberty.

Published: November 23, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Koliba P, Dibonová M, Bortelová K. Treatment of acne from a gynecologist's point of view. Dermatol. praxi. 2021;15(4):186-190. doi: 10.36290/der.2021.035.
Download citation

References

  1. Rob L, Martan A, Citterbart K. Gynekologie. Praha: Galén 2012: 319 s.
  2. O'Neill AM, Gallo RL. Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris. Microbiome 2018; 6: 177. Go to original source... Go to PubMed...
  3. Imperato-McGinley J, Gautier T, Cai LQ, et al. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 1993; 76: 524. Go to original source... Go to PubMed...
  4. Šarapatková H. Současný pohled na syndrom polycystických ovarií (online). Interní Med. 2008; 10(10): 461-465.
  5. Goulden V, Clark SM, Cunliffe WJ. Post-adolescent acne: a review of clinical features. Br J Dermatol 1997; 136: 66. Go to original source...
  6. Barbieri RL, Ehrmann DA. Diagnosis of polycystic ovary syndrome in adults, UpToDate, Literature review current through: Dec 2018, dostupné z: www.uptodate.com.
  7. Vrbíková J, Fanta M, Koryntová D. Syndrom polycystických ovarií. Praha: Maxdorf Jessenius 2014: 92 s.
  8. Rosenfield RL, Ehrmann DA. The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocr Rev 2016; 37: 467. Go to original source... Go to PubMed...
  9. Livadas S, Bothou C, Kanaka-Gantenbein C, et al. Unfavorable Hormonal and Psychologic Profile in Adult Women with a History of Premature Adrenarche and Pubarche, Compared to Women with Polycystic Ovary Syndrome. Horm Metab Res 2020; 52: 179. Go to original source... Go to PubMed...
  10. Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. Pediatrics 2013; 131(Suppl 3): S163. Go to original source... Go to PubMed...
  11. George R, Clarke S, Thiboutot D. Hormonal therapy for acne. Semin Cutan Med Surg 2008; 27: 188. Go to original source... Go to PubMed...
  12. Fait T. Antikoncepce. Praha: Maxdorf Jessenius 2018: 149 s.
  13. Arowojolu AO, Gallo MF, Lopez LM, Grimes DA. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev 2012; CD004425. Go to original source...
  14. Koulianos GT. Treatment of acne with oral contraceptives: criteria for pill selection. Cutis 2000; 66: 281. Go to PubMed...
  15. Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1. Go to original source... Go to PubMed...
  16. Koo EB, Petersen TD, Kimball AB. Meta-analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris. J Am Acad Dermatol 2014; 71: 450. Go to original source... Go to PubMed...
  17. Thiboutot D, Chen W. Update and future of hormonal therapy in acne. Dermatology 2003; 206: 57. Go to original source... Go to PubMed...
  18. Roberts EE, Nowsheen S, Davis MDP, et al. Treatment of acne with spironolactone: a retrospective review of 395 adult patients at Mayo Clinic, 2007-2017. J Eur Acad Dermatol Venereol 2020; 34: 2106. Go to original source... Go to PubMed...
  19. Sato K, Matsumoto D, Iizuka F, et al. Anti-androgenic therapy using oral spironolactone for acne vulgaris in Asians. Aesthetic Plast Surg 2006; 30: 689. Go to original source... Go to PubMed...
  20. Loughlin J, Seeger JD, Eng PM, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. Contraception 2008; 78: 377. Go to original source... Go to PubMed...
  21. Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. Dermatol Clin 2006; 24: 167. Go to original source... Go to PubMed...
  22. Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol 2014; 70: 401.e1. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.